ऑक्सीमॉर्फोन के इंटरैक्शन

हम जिन FDA लेबल और फैक्ट शीट को इंडेक्स करते हैं, उनमें ऑक्सीमॉर्फोन (Opana; ओपिओइड) के 351 इंटरैक्शन दर्ज हैं: 231 गंभीर, 104 मध्यम, 12 मामूली, और 4 ऐसे जिनमें लेबल बताता है कि कोई महत्वपूर्ण इंटरैक्शन नहीं है। नीचे की हर प्रविष्टि उस वाक्य को उद्धृत करती है जिस पर वह आधारित है। दवा का यह पेज एक शुरुआती बिंदु है, आपकी स्थिति के लिए कोई फ़ैसला नहीं।

लेबल से लिए गए इंटरैक्शन

गंभीर इंटरैक्शन (231)

  • अल्प्राज़ोलमबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • आइसोनियाज़िडएंटीबायोटिकगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • आइसोफ्लुरेनजनरल एनेस्थेटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • इमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • इलोपेरिडोनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एज़ेलास्टिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एज़ेलास्टिन और फ्लुटिकासोनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एटोमिडेटजनरल एनेस्थेटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एथोसक्सिमाइडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एमिट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एमोक्सापिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एरिपिप्राज़ोलएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एलक्साडोलिनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एलेट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एल्मोट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • …Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एल्विमोपैनओपिओइड एंटागोनिस्टगंभीर

    Alvimopan capsules are contraindicated in patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to taking alvimopan capsules [see Warnings and Precautions ( 5.3 )]. (एल्विमोपैन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • एसेनापिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एस्ज़ोपिक्लोनसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एस्टाज़ोलमबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • एस्लिकार्बाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सकार्बाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ऑक्साज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ऑक्सीकोडोनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ऑर्फेनाड्रिनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ओन्डैनसेट्रॉनQT अंतराल बढ़ाने वाली दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ओलिसेरिडिनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ओलैंज़ापिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ओलैंज़ापिन और फ्लुओक्सेटिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ओलोपाटाडीनएंटीहिस्टामिनगंभीर

    • Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (ओलोपाटाडीन लेबल, चेतावनियां और सावधानियां)

  • ओलोपाटाडीन और मोमेटासोनएंटीहिस्टामिनगंभीर

    • Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (ओलोपाटाडीन और मोमेटासोन लेबल, चेतावनियां और सावधानियां)

  • कार्बामाज़ेपिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • कार्बिनोक्सामिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • कीटोकोनाज़ोलएज़ोल एंटीफंगलगंभीर

    This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (कीटोकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • कीटोरोलैकNSAIDगंभीर

    BOXED WARNING Ketorolac tromethamine tablets, a nonsteroidal anti-inflammatory drug (NSAID), are indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. (कीटोरोलैक लेबल, बॉक्स्ड चेतावनी)

  • केटामिनCNS डिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • कैनाबिडियोल (प्रिस्क्रिप्शन दवा)एंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • कैरिप्राज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • कैरिसोप्रोडोलमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • कोडीनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लेमास्टिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोज़ापिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोनाज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोबाज़ामबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोरज़ोक्साज़ोनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोरडायज़ेपॉक्साइडबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोरप्रोमाज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोरफेनिरामिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्लोराज़ेपेटबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • क्वेटियापिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • गैबापेंटिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ग्रैनिसेट्रॉनQT अंतराल बढ़ाने वाली दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ग्वानफेसिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ज़िप्रासिडोनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ज़ेलेप्लॉनसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ज़ोनिसामाइडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ज़ोल्पिडेमसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ज़ोल्मिट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • टिज़ानिडिनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • टियागाबिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • टेट्राबेनाज़िनVMAT2 इनहिबिटरगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • टेपेंटाडोलओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • टेमाज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • टैसिमेल्टियॉनसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • टोपिरामेटएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ट्राइफ्लुओपेराज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ट्राइमिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ट्रामाडोलओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ट्रायज़ोलमबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ट्रैज़ोडोनएंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ट्रैनिलसाइप्रोमिनMAO इनहिबिटरगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डाइफेनहाइड्रामिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (डाइफेनोक्सिलेट और एट्रोपिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डाइमेनहाइड्रिनेटएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डाइवैल्प्रोएक्स (वैल्प्रोएट)एंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डाइहाइड्रोएर्गोटामिनएर्गोट एल्कलॉइडगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डायज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डारुनाविरएंटीरेट्रोवायरलगंभीर

    …elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (डारुनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • डारुनाविर और कोबिसिस्टैटएंटीरेट्रोवायरलगंभीर

    …elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma… (डारुनाविर और कोबिसिस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्सक्लोरफेनिरामिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डेक्सट्रोमेथॉर्फनसेरोटोनर्जिक दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्सट्रोमेथॉर्फन और क्विनिडिनसेरोटोनर्जिक दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्समेडेटोमिडिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डेसफ्लुरेनजनरल एनेस्थेटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डेसिप्रामिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डैंट्रोलीनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डैरिडोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डॉक्सीलामिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डॉक्सीलामिन और पाइरिडोक्सिनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • डॉक्सेपिनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ड्रोनाबिनोलकैनाबिनॉइडगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ड्रोपेरिडोलडोपामिन एंटागोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • थायोथिक्सीनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • थायोरिडाज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • नाराट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • नालबुफिनओपिओइडगंभीर

    Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) and partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxymorphone Hydrochloride Extended-Release Tablets. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • नालोक्सेगोलओपिओइड एंटागोनिस्टगंभीर

    …concomitantly using strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) because these medications can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms such as hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, and yawning [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)… (नालोक्सेगोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नालोक्सोनओपिओइड एंटागोनिस्टगंभीर

    In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. (नालोक्सोन लेबल, चेतावनियां और सावधानियां)

  • नाल्ट्रेक्सोनओपिओइड एंटागोनिस्टगंभीर

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (नाल्ट्रेक्सोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नाल्ट्रेक्सोन और ब्यूप्रोपियॉनओपिओइड एंटागोनिस्टगंभीर

    …limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN) Bulimia or anorexia nervosa, which increase the risk for seizure [see Warnings and Precautions (5.3) ] Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2)… (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नाल्डेमेडिनओपिओइड एंटागोनिस्टगंभीर

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

  • नाल्मेफीनओपिओइड एंटागोनिस्टगंभीर

    Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (नाल्मेफीन लेबल, चेतावनियां और सावधानियां)

  • …voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial… (निर्माट्रेल्विर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • नेफाज़ोडोनएंटीडिप्रेसेंटगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • नॉरट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • परफेनाज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • पिमावैनसेरिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • पिमोज़ाइडएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) and partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxymorphone Hydrochloride Extended-Release Tablets. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • पेथिडीनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • पेरैम्पेनलएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • पैलिपेरिडोनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • पैलोनोसेट्रॉनसेरोटोनर्जिक दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • प्रिमिडोनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • प्रीगैबलिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • प्रुकालोप्राइडसेरोटोनर्जिक दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • प्रैमिपेक्सोलडोपामिन एगोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • प्रोक्लोरपेराज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • प्रोट्रिप्टिलीनट्राइसाइक्लिक एंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • प्रोपोफोलCNS डिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • प्रोमेथाज़िनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फेंटरमिन और टोपिरामेटCNS स्टिमुलेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फेंटानिलओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फेनिटोइनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फेनेलज़िनMAO इनहिबिटरगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • फेनोबार्बिटोनबार्बिट्यूरेटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फेल्बामेटएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फॉस्फेनिटोइनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फोसएम्प्रेनाविरएंटीरेट्रोवायरलगंभीर

    …Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (फोसएम्प्रेनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • फ्रोवाट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • फ्लिबैनसेरिनCNS डिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • फ्लुफेनाज़िनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • फ्लुमाज़ेनिलबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • बस्पिरोनसेरोटोनर्जिक दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, दवाओं के इंटरैक्शन)

  • बेलाडोना और ओपियमओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • बैक्लोफेनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ब्यूटाल्बिटल और पैरासिटामोलबार्बिट्यूरेटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ब्यूटॉर्फेनॉलओपिओइडगंभीर

    Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) and partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxymorphone Hydrochloride Extended-Release Tablets. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • ब्यूप्रेनॉर्फिनओपिओइडगंभीर

    Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) and partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxymorphone Hydrochloride Extended-Release Tablets. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • Additionally, avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) and partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including Oxymorphone Hydrochloride Extended-Release Tablets. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • ब्रिवारासेटमएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ब्रेक्सपिप्राज़ोलएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मिडाज़ोलमबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मिथाइलनाल्ट्रेक्सोनओपिओइड एंटागोनिस्टगंभीर

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (मिथाइलनाल्ट्रेक्सोन लेबल, दवाओं के इंटरैक्शन)

  • मिथाइलीन ब्लूMAO इनहिबिटरगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • मिर्टाज़ापिनएंटीडिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • मेक्लिज़िनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेटाक्सालोनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेटोक्लोप्रामाइडडोपामिन एंटागोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेथसक्सिमाइडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेथाडोनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेथोकार्बामोलमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेथोहेक्सिटलबार्बिट्यूरेटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मेप्रोबामेटCNS डिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • मॉर्फिनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • रासाजिलिनMAO इनहिबिटरगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • रिज़ाट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • रिटोनाविरएंटीरेट्रोवायरलगंभीर

    WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (रिटोनाविर लेबल, बॉक्स्ड चेतावनी)

  • रिस्पेरिडोनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • रुफिनामाइडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • रेमिफेंटानिलओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • रैमेल्टियॉनसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • रोपिनिरोलडोपामिन एगोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लिथियमसेरोटोनर्जिक दवागंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • लिनेज़ोलिडएंटीबायोटिकगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • लुमाटेपेरोनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लेनाकैपाविरएंटीरेट्रोवायरलगंभीर

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (लेनाकैपाविर लेबल, दवाओं के इंटरैक्शन)

  • लेम्बोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लेवेटिरासेटमएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लेवॉर्फेनॉलओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • लेवोसेटिरिज़िनएंटीहिस्टामिनगंभीर

    Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (लेवोसेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

  • लैकोसामाइडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लोक्सापिनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लोपिनाविर और रिटोनाविरएंटीरेट्रोवायरलगंभीर

    …Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics:… (लोपिनाविर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

  • लोफेक्सिडिनअल्फा-एड्रीनर्जिक एगोनिस्टगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • लोराज़ेपामबेंज़ोडायज़ेपिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • ल्यूरासिडोनएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • विगाबैट्रिनएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • वैल्प्रोइक एसिडएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • वोर्टियोक्सेटिनएंटीडिप्रेसेंटगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • शराब (अल्कोहल)शराब (अल्कोहल)गंभीर

    Interaction with Alcohol Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking Oxymorphone Hydrochloride Extended-Release Tablets. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोबेंज़ाप्रिनमसल रिलैक्सेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • साइप्रोहेप्टाडीनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • सिप्रोफ्लॉक्सासिनफ्लुओरोक्विनोलोनगंभीर

    Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (सिप्रोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

  • सिमेटिडीनH2 ब्लॉकरगंभीर

    Cimetidine Clinical Impact: Cimetidine can potentiate opioid-induced respiratory depression. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • सुमाट्रिप्टानट्रिप्टानगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • सुवोरेक्सेंटसेडेटिव-हिप्नोटिक (नींद की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • सेटिरिज़िनएंटीहिस्टामिनगंभीर

    Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (सेटिरिज़िन लेबल, चेतावनियां और सावधानियां)

  • सेनोबामेटएंटीकन्वल्सेंट (दौरे की दवा)गंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • सेलेजिलिनMAO इनहिबिटरगंभीर

    Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.2) ]. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • सेवोफ्लुरेनजनरल एनेस्थेटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • सोडियम ऑक्सीबेटCNS डिप्रेसेंटगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • सोलरियमफेटोलCNS स्टिमुलेंटगंभीर

    Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • स्कोपोलामाइन (हायोसिन)एंटीकोलिनर्जिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रॉक्सीज़िनएंटीहिस्टामिनगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रोकोडोनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • हाइड्रोमॉर्फोनओपिओइडगंभीर

    …HYDROCHLORIDE EXTENDED-RELEASE TABLETS Addiction, Abuse, and Misuse Because the use of Oxymorphone Hydrochloride Extended-Release Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of… (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

  • हेलोपेरिडोलएंटीसाइकोटिकगंभीर

    Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (ऑक्सीमॉर्फोन लेबल, बॉक्स्ड चेतावनी)

मध्यम इंटरैक्शन (104)

  • अमैंटाडिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • इंडापामाइडथायज़ाइड डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • इप्राट्रोपियमएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • इप्राट्रोपियम और सैल्बुटामोलएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • इर्बेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एक्लिडिनियमएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एटाज़ानाविरएंटीरेट्रोवायरलमध्यम

    Opioids: buprenorphine REYATAZ or REYATAZ with ritonavir ↑ buprenorphine ↑ norbuprenorphine Coadministration of REYATAZ with ritonavir and buprenorphine warrants clinical monitoring for sedation and cognitive effects. (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

  • एटेनोलोल और क्लोरथैलिडोनबीटा ब्लॉकरमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एट्राविरिनएंटीरेट्रोवायरलमध्यम

    Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

  • एट्रोपिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एट्रोपिन और प्रैलिडॉक्सिमएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एथाक्रिनिक एसिडलूप डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एप्लेरेनोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एफाविरेंज़एंटीरेट्रोवायरलमध्यम

    Narcotic analgesic: Methadone ↓ methadone * Monitor for signs of methadone withdrawal and increase methadone dose if required to alleviate withdrawal symptoms. * The interaction between efavirenz and the drug was evaluated in a clinical study. (एफाविरेंज़ लेबल, दवाओं के इंटरैक्शन)

  • Narcotic analgesic: Methadone ↓ methadone Monitor for signs of methadone withdrawal and increase methadone dose if required to alleviate withdrawal symptoms. (एफाविरेंज़, लैमिवुडिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

  • एमिनोफाइलिनमिथाइलज़ैंथिनमध्यम

    25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • एमिलोराइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • एलोप्यूरिनॉलज़ैंथिन ऑक्सीडेज़ इनहिबिटरमध्यम

    Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (एलोप्यूरिनॉल लेबल, चेतावनियां और सावधानियां)

  • एसिटाज़ोलामाइडकार्बोनिक एनहाइड्रेज़ इनहिबिटरमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ऑक्सीब्यूटिनिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ओल्मेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • कैंडेसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • क्लोपिडोग्रेलएंटीप्लेटलेट दवामध्यम

    Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

  • क्लोबेटासोलकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • क्लोरथैलिडोनथायज़ाइड डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • क्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ग्लाइकोपाइरोलेटएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • टिकाग्रेलोरएंटीप्लेटलेट दवामध्यम

    • Opioids: Decreased exposure to ticagrelor. (टिकाग्रेलोर लेबल, दवाओं के इंटरैक्शन)

  • टियोट्रोपियमएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • टेल्मिसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • टॉरसेमाइडलूप डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • टोल्टेरोडिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

  • ट्राइहेक्सीफेनिडिलएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमटेरिनपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमटेरिन और हाइड्रोक्लोरोथायज़ाइडपोटैशियम-स्पेयरिंग डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ट्रायमसिनोलोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • ट्रोस्पियमएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • MOTOFEN ® may potentiate the action of barbiturates, tranquilizers, narcotics, and alcohol. (डाइफेनॉक्सिन और एट्रोपिन लेबल, दवाओं के इंटरैक्शन)

  • डाइसाइक्लोमिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डाइसोपाइरामाइडएंटीएरिदमिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • डेक्सामेथासोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • डेफ्लाज़ाकॉर्टकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • डेसोनाइडकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (डेस्मोप्रेसिन लेबल, दवाओं के इंटरैक्शन)

  • डैरिफेनासिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ड्यूटेट्राबेनाज़िनVMAT2 इनहिबिटरमध्यम

    Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (ड्यूटेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

  • थियोफाइलिनमिथाइलज़ैंथिनमध्यम

    25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

  • निफेडिपिनडाइहाइड्रोपाइरिडीन कैल्शियम चैनल ब्लॉकरमध्यम

    The interaction with high-dose fentanyl appears to be due to the combination of nifedipine and a beta-blocker, but the possibility that it may occur with nifedipine alone, with low doses of fentanyl, in other surgical procedures, or with other narcotic analgesics cannot be ruled out. (निफेडिपिन लेबल, चेतावनियां)

  • नेविरापिनएंटीरेट्रोवायरलमध्यम

    Other Agents Analgesics: Methadone ↓ Methadone Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. (नेविरापिन लेबल, दवाओं के इंटरैक्शन)

  • पोसाकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (पोसाकोनाज़ोल लेबल, चेतावनियां और सावधानियां)

  • प्रासुग्रेलएंटीप्लेटलेट दवामध्यम

    Opioids: Decreased exposure to prasugrel. (प्रासुग्रेल लेबल, दवाओं के इंटरैक्शन)

  • प्रेडनिसोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • प्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • फेसोटेरोडिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • फ्यूरोसेमाइडलूप डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • फ्लुओसिनोनाइडकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • फ्लुटिकासोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • फ्लुटिकासोन और सैल्मेटेरोलकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • फ्लुड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • फ्लुनिसोलाइडकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • फ्लेवोक्सेटएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • बीटामेथासोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • बुडेसोनाइडकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • बुडेसोनाइड और फॉर्मोटेरोलकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • बुमेटेनाइडलूप डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • बेंज़ट्रोपिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • बेक्लोमेथासोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूपिवाकेनलोकल एनेस्थेटिकमध्यम

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन लेबल, चेतावनियां और सावधानियां)

  • ब्यूपिवाकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (ब्यूपिवाकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

  • ब्रिमोनिडिनअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन लेबल, दवाओं के इंटरैक्शन)

  • ब्रिमोनिडिन और टिमोलोलअल्फा-एड्रीनर्जिक एगोनिस्टमध्यम

    Use with CNS depressants may result in an additive or potentiating effect. (ब्रिमोनिडिन और टिमोलोल लेबल, दवाओं के इंटरैक्शन)

  • मिथाइलप्रेडनिसोलोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (मेटाइरोसिन लेबल, दवाओं के इंटरैक्शन)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • मेटोलाज़ोनथायज़ाइड डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • मेथस्कोपोलामाइनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • मोमेटासोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • यूमेक्लिडिनियमएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • यूमेक्लिडिनियम और विलैंटेरोलएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • रिफापेंटिनएंटीबायोटिकमध्यम

    …Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions… (रिफापेंटिन लेबल, दवाओं के इंटरैक्शन)

  • रिफैम्पिसिनएंटीबायोटिकमध्यम

    Decrease AUC by 56% Narcotic Analgesics Oxycodone Decrease AUC by 86% Morphine Decrease exposure Progestin Antagonist Mifepristone Prevention or Management: Refer to the posttreatment assessment in the mifepristone prescribing information to verify that treatment has been successful. (रिफैम्पिसिन लेबल, दवाओं के इंटरैक्शन)

  • रोक्यूरोनियमन्यूरोमस्कुलर ब्लॉकरमध्यम

    Isoflurane and enflurane may also prolong the duration of action of initial and maintenance doses of Rocuronium Bromide Injection and decrease the average infusion requirement of Rocuronium Bromide Injection by 40% compared to opioid/nitrous oxide/oxygen anesthesia. (रोक्यूरोनियम लेबल, दवाओं के इंटरैक्शन)

  • लिडोकेन और एड्रेनालिनलोकल एनेस्थेटिकमध्यम

    Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (लिडोकेन और एड्रेनालिन लेबल, चेतावनियां और सावधानियां)

  • Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Methadone Diphenylheptane opioids (e.g., methadone) have been shown in nonclinical studies to dose-dependently reduce the activation of ClC-2 by lubiprostone in the gastrointestinal tract. (लुबिप्रोस्टोन लेबल, दवाओं के इंटरैक्शन)

  • लोसार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • वाल्सार्टन और हाइड्रोक्लोरोथायज़ाइडएंजियोटेंसिन II रिसेप्टर ब्लॉकर (ARB)मध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • वोरिकोनाज़ोलएज़ोल एंटीफंगलमध्यम

    Fentanyl (CYP3A4 Inhibition) Increased Reduction in the dose of fentanyl and other long-acting opiates metabolized by CYP3A4 should be considered when concomitantly administered with voriconazole. (वोरिकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

  • साइक्लोपेंटोलेटएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • सिक्लेसोनाइडकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • सोलिफेनासिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • स्पिरोनोलैक्टोनएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • स्पिरोनोलैक्टोन और हाइड्रोक्लोरोथायज़ाइडएल्डोस्टेरोन एंटागोनिस्टमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • हाइड्रोकॉर्टिसोनकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

  • हाइड्रोक्लोरोथायज़ाइडथायज़ाइड डाइयूरेटिकमध्यम

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • हायोसायमिनएंटीकोलिनर्जिकमध्यम

    Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • हेलोबेटासोलकॉर्टिकोस्टेरॉइडमध्यम

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (ऑक्सीमॉर्फोन लेबल, चेतावनियां और सावधानियां)

मामूली ज़िक्र (12)

  • इन्फ्लिक्सिमैबइम्यूनोसप्रेसेंटमामूली

    In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. (इन्फ्लिक्सिमैब लेबल, दवाओं के इंटरैक्शन)

  • एटोमोक्सेटिननॉरएपिनेफ्रिन रीअपटेक इनहिबिटरमामूली

    Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase… (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (एपोएटिन अल्फा लेबल, चेतावनियां और सावधानियां)

  • ओफ्लॉक्सासिनफ्लुओरोक्विनोलोनमामूली

    Interaction With Laboratory or Diagnostic Testing Some quinolones, including ofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. (ओफ्लॉक्सासिन लेबल, सावधानियां)

  • डेक्सट्रोएम्फेटामाइनCNS स्टिमुलेंटमामूली

    Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

  • In Postanesthetic Use Doxapram is neither an antagonist to muscle relaxant drugs nor a specific narcotic antagonist. (डॉक्साप्राम लेबल, चेतावनियां)

  • पाइरिडोस्टिग्मिनकोलिनेस्टेरेज़ इनहिबिटरमामूली

    Narcotics: Exacerbation of bradycardia possible. (पाइरिडोस्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

  • प्राज़ोसिनअल्फा ब्लॉकरमामूली

    …to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (प्राज़ोसिन लेबल, दवाओं के इंटरैक्शन)

  • ब्यूप्रोपियॉनएंटीडिप्रेसेंटमामूली

    Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase… (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (लेनालिडोमाइड लेबल, चेतावनियां और सावधानियां)

  • लेवोफ्लॉक्सासिनफ्लुओरोक्विनोलोनमामूली

    Interactions with Laboratory or Diagnostic Testing Some fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. (लेवोफ्लॉक्सासिन लेबल, दवाओं के इंटरैक्शन)

  • विलोक्साज़िननॉरएपिनेफ्रिन रीअपटेक इनहिबिटरमामूली

    Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase… (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

कोई महत्वपूर्ण इंटरैक्शन नहीं बताया गया (4)

  • एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविरएंटीरेट्रोवायरलकोई इंटरैक्शन नहीं

    Narcotic Analgesics : methadone ↓ R(–) methadone ↓ S(+) methadone ↔ RPV ↔ methadone (when used with tenofovir) No dose adjustments are required when initiating coadministration of methadone with COMPLERA. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

  • मोंटेलुकास्टल्यूकोट्राइन रिसेप्टर एंटागोनिस्टकोई इंटरैक्शन नहीं

    …adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)

  • राल्टेग्राविरएंटीरेट्रोवायरलकोई इंटरैक्शन नहीं

    Based on these data, ISENTRESS is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or P-glycoprotein (e.g., protease inhibitors, NNRTIs, opioid analgesics, statins, azole antifungals, proton pump inhibitors and anti-erectile dysfunction agents). (राल्टेग्राविर लेबल, दवाओं के इंटरैक्शन)

  • रिल्पिविरिनएंटीरेट्रोवायरलकोई इंटरैक्शन नहीं

    Narcotic Analgesics: methadone ↓ R(-) methadone ↓ S(+) methadone No dose adjustments are required when initiating coadministration of methadone with EDURANT or EDURANT PED. (रिल्पिविरिन लेबल, दवाओं के इंटरैक्शन)

आप जो कुछ भी लेते हैं, उस सबके साथ ऑक्सीमॉर्फोन को जांचें। अपनी पूरी सूची जोड़ें; हर जोड़ी एक साथ जांची जाती है।

चेकर में खोलें

यह चिकित्सकीय सलाह नहीं है। गंभीरता लेबल के शब्दों को दर्शाती है, आपकी परिस्थितियों को नहीं। “गंभीर” चिह्न वाला संयोजन डॉक्टर की देखरेख में सामान्य बात हो सकता है, और “मामूली” चिह्न वाला संयोजन ऊंची खुराक पर मायने रख सकता है। फार्मासिस्ट से पूछें।